Hi
I'd like to hear from several users of Montelukast as to how long they feel it took to get an improvement in their symptoms. Hoping to get several answers so I can compare them and arrive at an average time-frame I should expect to wait on any positive results (assuming I'm lucky enough for this drug to work for me).
Thanks in anticipation.
**UPDATE 3rd March 2017
Thanks to everyone kind enough to respond. By way of reciprocation, I've added a below a possibly useful extract concerning this Drug Class - in particular the comments concerning zileuton were of interest. While I can't immediately relocate the source, if you want to find it you could try entering a sentence or two into Google and checking out the results - many of which will probably relate to Aspirin Intolerance and Asthma BUT there's a broader message here too about the benefits of this class of drugs, here's the extract:
'....Both leukotriene-receptor antagonists (LTRAs) (eg, montelukast, zafirlukast) [38,39,65,66] and inhibitors of leukotriene synthesis (eg, zileuton) [37,67] are effective in AERD. The general use of LTMAs in asthma is reviewed separately (figure 3 and table 2). (See "Agents affecting the 5-lipoxygenase pathway in the treatment of asthma".)
As a practical matter, most clinicians select an oral LTRA (montelukast, zafirlukast) for initial therapy, rather than the 5-lipoxygenase (5-LO) inhibitor zileuton, as zileuton requires twice daily administration, periodic monitoring of liver function tests, and has some potential drug interactions. If patients do not improve with the LTRA after four to six weeks, then zileuton may be added or substituted. In a survey of patients with AERD, respondents identified zileuton as "extremely effective" more often than LTRAs [47].
●A randomized trial compared montelukast with placebo in 80 patients with asthma and NSAID intolerance, the majority of whom required inhaled or oral glucocorticoids to control their symptoms [65]. Four weeks of treatment with montelukast was associated with a 10 percent increase in forced expiratory volume in one second (FEV1), higher morning peak flow rates, decreased use of rescue medication, and a significant improvement in asthma quality of life scores. The montelukast group also experienced 54 percent fewer asthma exacerbations.
●A randomized trial evaluated the effect of six weeks of treatment with the 5-LO inhibitor zileuton (600 mg, four times daily) in 40 patients with AERD [67]. Existing therapy was continued, which included medium to high doses of inhaled (average daily dose >1000 micrograms of beclomethasone or budesonide) or oral glucocorticoids (4 to 25 mg daily) for all but one patient. The addition of zileuton compared with placebo resulted in both immediate and ongoing improvement in pulmonary function and lower use of short-acting beta-agonists for symptom relief. Zileuton also alleviated nasal symptoms, including rhinorrhea, congestion, and impaired sense of smell. Furthermore, zileuton produced a small reduction of bronchial hyperresponsiveness to histamine.
While the simultaneous use of zileuton and a LTRA has not been formally studied, it has been mentioned in case series and reviews [68-70]. It is thought that combination therapy may be advantageous in patients who do not achieve disease control with either of the individual agents. The rationale for combination therapy is based upon studies demonstrating that patients with AERD have elevated cysteinyl leukotriene (cysLT) levels and receptor numbers, as well as upregulation of 5-LO. Thus, combination therapy may address these abnormalities more completely.
...'
Seen this published Friday about Shielding
Montelukast 
Montelukast
Montelukast 
Montelukast and asthma
